Search
Now showing items 51-60 of 68
Organic solvents and Multiple Sclerosis: the doubled risk dilemma.
(2023-09-29)
BACKGROUND: Compensation for industrial disease in the UK may be obtained in two ways. A State scheme includes a list of accepted associations between occupations and diseases with evidence of a causative association. ...
Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis.
(2023)
BACKGROUND: Cladribine is an effective immunotherapy for people with multiple sclerosis (pwMS). Whilst most pwMS do not require re-treatment following standard dosing (two treatment courses), disease activity re-emerges ...